Alixorexton, an experimental oral therapy from Alkermes, reduced daytime sleepiness and fatigue while boosting wakefulness and cognitive function in the Phase 2 Vibrance-2 study for narcolepsy type 2 (NT2). “People living with narcolepsy type 2 frequently experience a lengthy and challenging diagnostic journey, and many continue to live…
News
Takeda’s experimental therapy oveporexton helped people with narcolepsy type 1 (NT1) improve measures of nighttime sleep, daily functioning, and cognitive symptoms. That’s according to additional data from secondary and exploratory endpoints from two now-completed global Phase 3 studies, FirstLight (NCT06470828) and RadiantLight (NCT06505031), presented at SLEEP…
A custom-fit, in-ear electroencephalography (EEG) device that records the brain’s electrical activity may be a possible alternative to traditional in-laboratory sleep studies for diagnosing narcolepsy, a new study suggests. According to researchers, the new, wearable EEG device showed substantial agreement with standard sleep studies for overnight sleep staging, as…
Testing cerebrospinal fluid for fragments of the signaling molecule hypocretin-1 could help identify narcolepsy type 1 (NT1) and, potentially, track the disease’s progression more consistently than current diagnostic methods, a study found. Part of differentiating NT1 from narcolepsy type 2 (NT2) or other sleep disorders involves testing for…
Xywav (calcium, magnesium, potassium, and sodium oxybates), an approved medication for narcolepsy, is effective in easing disease symptoms, working to both reduce excessive daytime sleepiness and improve nighttime sleep quality in people with the rare sleep-related disorder. That’s according to newly published results from the Phase 4…
Focusing on sleep spindles, a type of brain wave that’s recorded during sleep studies, may help researchers differentiate type 1 narcolepsy from another condition that causes daytime sleepiness, according to a new study from scientists in Japan. The team of scientists used automated analyses of sleep studies, or polysomnography,…
Use of the stimulant dexamphetamine during pregnancy to treat narcolepsy is not linked to harmful outcomes for mothers or their newborns, according to a small case series in Australia. The researchers reported that, among 10 pregnant women with narcolepsy or idiopathic hypersomnolence — excessive daytime sleepiness due to unknown…
Type 1 narcolepsy has long been linked to the loss of nerve cells called hypocretin neurons in a brain region called the hypothalamus, but a new study suggests damage to a second brain region, called the locus coeruleus, is also involved. This finding may help explain why people with…
Adults with type 1 narcolepsy (NT1) — generally the more severe disease type — often deal with symptoms beyond just uncontrollable sleepiness, including internalizing emotional and behavioral challenges that others tend to underestimate, a study suggests. Combining reports from both patients and close observers — family members and friends…
People with type 1 narcolepsy (NT1) may have changes in how their brain fluid barrier functions, a new study suggests. Lower levels of the water channel protein aquaporin-4 (AQP4), responsible for water balance and perivascular fluid movement (the flow of cerebrospinal fluid through spaces surrounding blood vessels in the…
Recent Posts
- Getting my dad’s perspective on how I’m living with narcolepsy
- Study tracks narcolepsy incidence, healthcare costs in France
- Exploratory study IDs protein that may help in diagnosing narcolepsy
- NapChat helped me find my voice as a narcolepsy advocate
- Daytime sleep patterns may aid narcolepsy diagnosis, study finds